Manejo médico de la osteoartrosis con glucosamina y condrotin sulfato

Edgar J. Nieto

doi:10.47196/rar.v25i3.88

Edgar J. Nieto Universidad de Los Andes, Mérida, Venezuela

DOI: https://doi.org/10.47196/rar.v25i3.88

Palabras clave: osteoartritis, fármaccos

Resumen

De las patologías inflamatorias articulares, la osteoartrosis u osteoartritis (OA) es la forma más común, la principal causa de incapacidad en el adulto mayor, y a nivel de salud pública su impacto sigue en constante aumento y de manera especial en ancianos obesos. Hasta el día de hoy, no existe tratamiento definitivo para evitar su aparición o detener su progresión. Una mejor comprensión de la fisiopatología de la OA y a nivel clínico el desarrollo de biomarcadores más sensibles o estudios no invasivos, para identificar y poner a prueba los tratamientos, podrían reducir la carga de esta enfermedad común.

Biografía del autor/a

Edgar J. Nieto, Universidad de Los Andes, Mérida, Venezuela

Profesor Titular de Ortopedia y Traumatología

Citas

I. Guccione AA. Arthritis and the process of disable-ment. Bibliografia. Phys Ther. 1994 May; 74(5):408-14.

II. Laba TL, Brien JA, Fransen M, Jan S. Patient preferences for adherence to treatment for osteoarthritis: the ME-dication Decisions in Osteoarthritis Study (MEDOS). BMC Musculoskelet Disord. 2013 May 6; 14(1):160.

III. Loeser RF: Aging and osteoarthritis. Curr Opin Rheumatol 2011, 23:492-496.

IV. Shane Anderson A, Loeser RF: Why is osteoarthritis an age-related disease? Best Pract Res Clin Rheuma-tol 2010; 24:15-26.

V. Dieppe P. Developments in osteoarthritis. Rheuma-tology (Oxford). 2011 Feb; 50(2):245-7.

VI. Haviv B, Bronak S, Thein R. The complexity of pain around the knee in patients with osteoarthritis. Isr Med Assoc J. 2013 Apr; 15(4):178-81.

VII. Neogi T, Bowes MA, Niu J, et al.Magnetic resonance imaging-based three-dimensional bone shape of the knee predicts onset of knee osteoarthritis: data from the osteoarthritis initiative. Arthritis Rheum. 2013 Aug; 65(8):2048-58

VIII. Mobasheri A. The future of osteoarthritis thera-peutics: targeted pharmacological therapy. Curr Rheumatol Rep. 2013 Oct; 15(10):364.

IX. Towheed T, Maxwell L, Anastassiades TP, Shea B et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; (2):CD002946.

X. Pearle A, Warren R, Rodeo S. Basic science of arti-cular cartilage and osteoarthritis. Clin Sports Med 2005; 24:1-12.

XI. Nakamura H, Shibakawa A, Tanaka M, et al. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol. 2004; 22(3):293-9.

XII. Lin YC, Liang YC, Sheu MT, Lin YC et al. Chondro-protective effects of glucosamine involving the p38 MAPK and Akt signaling pathways. Rheumatol Int. 2008; 28(10):1009-16.

XIII. Mendis E, Kim MM, Rajapakse N, Kim SK. The in-hibitory mechanism of a novel cationic glucosamine derivative against MMP-2 andMMP-9 expressions. Bioorg Med Chem Lett. 2009; 19(10):2755-9.

XIV. Imagawa K, de Andres MC, Hashimoto K, Pitt D, et al. The epigenetic effect of glucosamine and a nu-clear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes-implications for osteoarthritis. Biochem Biophys Res Commun. 2011; 405(3):362-7.

XV. Largo R, Alvarez-Soria MA, Díez-Ortego I, Cal-vo E, et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chon-drocytes. Osteoarthritis Cartilage 2003; 11:290-298.

XVI. Chan PS, Caron JP. Short-term gene expression changes in cartilage explants stimulated with inter-leukin beta plus glucosamine and chondroitin sulfate. J Rheumatol 2006; 33:1329-1340.

XVII. Oegema TRJr, Deloria LB, Sandy JD, Hart DA. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 2002; 46:2495-2503.

XVIII. Chan PS, Caron JP. Orth MW. Effect of glucosamine and chondroitin sulfate on regulation of gene expres-sion of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine Am J Vet Res. 2005 Nov; 66(11):1870-6.

XIX. Wen CH, Tang CC, Chang YC, Huang SY, et al. Glucosamine sulfate reduces experimental osteoar-thritis and nociception in rats: association with changes of mitogen-activated protein kinase in chon-drocytes. Wen ZH, Osteoarthritis Cartilage. 2010 Sep; 18(9):1192-202.

XX. Naito K, Watari T, Furuhata A, Yomogida S, et al. Evaluation of the effect of glucosamine on an experi-mental rat osteoarthritis model. Life Sci. 2010 Mar 27; 86(13-14):538-43.

XXI. Tiraloche G, Girard C, Chouinard L, Sampalis J, et al Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis.. Arthritis Rheum. 2005 Apr; 52(4):1118-28.

XXII. Kim MM, Mendis E, Rajapakse N, Kim S-K. Gluco-samine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect. Bioorg Med Chem Lett. 2007; 17(7):1938-42.

XXIII. Henrotin Y, Mobasheri A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther. 2012 Jan 30; 14(1):201.

XXIV. Persiani S, Roda E, RovatiL C, Locatelli M, et al.Glucosamine oral bioavailability and plasma phar-macokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthr Cartil. 2005; 6:1041-1049.

XXV. Henrotin Y, Chevalier X, Herrero-Beaumont G, McAlindon T, et al. Physiological effects of oral glucosamine on joint health: current status and con-sensus on future research priorities.BMC Res Notes. 2013 Mar 26; 6:115.

XXVI. ShermanAL, Ojeda-Correal G, Mena J, Clinical sig-nificance of bone changes in osteoarthritis Ther Adv Musculoskel Dis. 2012; 4(4):259-267.

XXVII. Monfort J, Pelletier J-P, Garcia-Giralt N, Martel-Pe-lletier J. Biochemical basis of the effect of chondroitin sulfate on osteoarthritis articular tissues. Ann Rheum Dis 2008; 67:735-740.

XXVIII. Hochberg MC. Structure-modifying effects of chon-droitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 2010; 18(Suppl 1):S28e31.

XXIX. Miller KL, Clegg DO. Glucosamine and chondroi-tin sulfate. Rheum Dis Clin North Am. 2011 Feb; 37(1):103-18.

XXX. Zegels B, Crozes P, Uebelhart D, Bruyère O, Re-ginster JY. Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee os-teoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis Cartilage. 2013 Jan; 21(1):22-7.

XXXI. Zhang W, Doherty M, Leeb BF, Alekseeva L, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for In-ternational Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007; 66(3):377-88.

XXXII. Bruyère O, Cooper C, Pelletier JP, Branco J, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 May 14. pii: S0049-0172(14)00108-5. doi: 10.1016/j.semarthrit.2014.05.014.

XXXIII. Zhang W, Nuki G, Moskowitz RW, et al. OARSI re-commendations for the management of hip and knee osteoarthritis: Part III: changes in evidence following systematic cumulative update of research publis-hed through January 2009. Osteoarthr Cartil. 2010; 18(4):476-99.

XXXIV. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar; 22(3):363-88.

XXXV. NICE Clinical Guidelines: The care and manage-ment of osteoarthritis in adults [www.nice.org.uk/ CG059]

XXXVI. Hochberg MC, Altman RD, April KT, Benkhalti M et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012; 64(4):465-74.

XXXVII. Gallagher B, Tjoumakaris FP, Harwood MI, Good RP, et al. Chondroprotection and the Prevention of Osteoarthritis Progression of the Knee: A Systematic Review of Treatment Agents. Am J Sports Med. 2014 May 27. pii: 0363546514533777

XXXVIII. Martin MS1, Van Sell S, Danter J. Glucosamine and chondroitin: an appropriate adjunct treatment of symptomatic osteoarthritis of the knee. Orthop Nurs. 2012 May-Jun; 31(3):160-6.

XXXIX. Primeras guías argentinas de práctica clínica para el diagnóstico y tratamiento de la osteoartritis (OA) de caderas, rodillas y manos. Sociedad Argentina de Reumatología; Edición 2010.

XL. Henrotin Y, Marty M, Mobasheric A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014 Jul; 78(3):184-187.

XLI. Francisco Abad Santos, Dolores Ochoa y Antonio G. García Actualización de la eficacia de condroitín sulfato y sulfato de glucosamina en el tratamiento de la artrosis. Actualidad en Farmacología y Terapéutica junio 2011.Volumen 9(2):97-108.

XLII. Clegg DO, Reda DJ, Harris CL, Klein MA, et al. Glucosamine, chondroitin sulfate, and he two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354:795-808.

XLIII. National Center for Complimentary and Alternative Medicine. The NIH Glucosamine/Chondroitin Ar-thritis Intervention Trial (GAIT). J Pain Palliat Care Pharmacother. 2008; 22(1):39-43.

XLIV. Hochberg MC, Clegg DO. Potential effects of chon-droitin sulfate on joint swelling: a GAIT report. Osteoarthritis Cartilage 2008; 16 (Supl 3):S22-4.

XLV. Sawitzke AD, Shi H, Finco MF, Dunlop DD, et al. Cli-nical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis. 2010 Aug; 69(8):1459-64.

XLVI. Wandel S, Juni P, Tenda l B, Nuesch E, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ.2010; 341:c4675.

XLVII. Pelletier JP, Hochberg MC, du Souich P, Kahan A, Michel BA. Glucosamine and osteoarthritis. Effect size is encouraging. BMJ. 2010 Nov 9; 341.

XLVIII. Reginster JY, Deroisy R, RovatiL C, Lee RL, Lejeu-ne E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001 Jan 27; 357(9252):251-6.

XLIX. Reginster JY, Altman RD, Hochberg MC. Pres-cription glucosamine sulphate is effective in knee osteoarthritis. BMJ 2010; response to 341:c4675

L. H elg A.G. Critical appraisal of the meta-analy-sis by Wandel et al. - clinical aspects (part 1). http://www.bmj.com/rapid-response/2011/11/03/ critical-appraisal-meta-analysis-wandel-et-al-clini-cal-aspects-part-1

LI. Groves T (2011). Bmj.com.2010.www.bmj.com/content/341/bmj.c4675

LII. Garcia AG. Controversias en el tratamiento de la ar-trosis con glucosaminoglicanos Editorial. Actualidad en Farmacología y Terapéutica. Junio 2011; volumen 9(2): 85-91.

LIII. Fransen M, Agaliotis M, Nairn L, Votrubec M, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clini-cal trial evaluating single and combination regimens. Ann Rheum Dis. 2014 Jan 6. doi: 10.1136/annrheum-dis-2013-203954.

LIV. Henrotin YE. Interpretation of metaanalyses: pit-falls should be more widely recognized. J Rheumatol. 2012 Jun; 39(6):1107-9.

LV. Block JA, Oegema TR, Sandy JD, Plaas A. The effects of oral glucosamine on joint health: is a change in research approach needed? Osteoarthritis Cartila-ge.2010; 18:5-11.

LVI. Sodha R, Sivanadarajah N, Alam M. The use of glu-cosamine for chronic low back pain: a systematic review of randomised control trials. BMJ Open. 2013 Jun 20; 3(6).

LVII. Calamia V, Ruiz-Romero C, Rocha B, et al. Pharma-coproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondro-cytes. Arthritis Res Ther. 2010;6:R138

LVIII. Uitterlinden EJ, Jahr H, Koevoet JL, Bierma-Zeins-tra SM, et al. Glucosamine reduces anabolic as well as catabolic processes in bovine chondrocytes cultu-red in alginate. Osteoarthritis Cartilage. 2007 Nov; 15(11):1267-7.

LIX. Davies PS, Graham SM, MacFarlane RJ, et al. Di-sease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation. Expert Opin Investig Drugs. 2013 Apr; 22(4):423-41.

LX. Reginster JY, Deroisy R, Rovati LC, Lee RL et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001; 6:251-256.

LXI. Pavelka K, Gatterova J, Olejarova M, Machacek S et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, place-bo-controlled, double-blind study. Arch Intern Med. 2002; 6:2113-2123.

LXII. Ostojic SM, Arsic M, Prodanovic S, Vukovic J et al. Glucosamine administration in athletes: effects on recovery of acute knee injury. Res Sports Med. 2007; 6:113-124.

LXIII. Chen HC, Shah S, Stabler TV, Li YJ et al. Biomar-kers associated with clinical phenotypes of hand osteoarthritis in a large multigenerational family: the CARRIAGE family study. Osteoarthr Cartil. 2008; 6:1054-1059.

LXIV. Ohnishi A, Osaki T, Matahira Y, Tsuka T et al. Evaluation of the chondroprotective effects of gluco-samine and fish collagen peptide on a rabbit ACLT model using serum biomarkers. J Vet Med Sci. 2013 May 2; 75(4):421-9.

LXV. Erickson JM, Messer TM. Glucosamine and chon-droitin sulfate treatment of hand osteoarthritis. J Hand Surg Am. 2013 Aug; 38(8):1638-40.

LXVI. Bell GA, Kantor ED, Lampe JW, Shen DD et al. Use of Glucosamine and Chondroitin in Relation to Mor-tality. Eur J Epidemiol. 2012 August; 27(8): 593-603. doi:10.1007/s10654-012-9714-6.

LXVII. Simon RR, Marks V, Leeds AR, Anderson JW. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev. 2011; 6:14-27.

LXVIII. Bertin P, Taieb C. NSAID-sparing effect of glu-cosamine hydrochloride in patients with knee osteoarthritis: an analysis of data from a French data-base. Curr Med Res Opin 2014; 30:271-7.